VistA-internationalization/TranslationSpreadsheets/WV-DIALOG-0234.txt

308 lines
14 KiB
Plaintext

English French Notes Complete/Exclude
GRADE/DIFFERENTIATION must be: 2 (Grade II)
GRADE/DIFFERENTIATION must be: 4 (Grade IV)
GRADE/DIFFERENTIATION =
HISTOLOGY must be leukemia or lymphoma (9590-9948)
No TNM classification is available for LYMPHOMA
SUMMARY STAGE cannot be blank
No TNM classification is available for KAPOSI'S SAROMA
EXTENSION may not be 00 (In situ)
ICDO-TOPOGRAPHY =
PATHOLGIC EXTENSION =
PATHOLOGIC EXTENSION may only be coded for PROSTATE (C61.9) cases
REGIONAL NODES POSITIVE =
LYMPH NODES may not be 0 (No lymph nodes)
REGIONAL NODES EXAMINED = 99 (
REGIONAL NODES POSITIVE must be 99 (Unk if nodes + or -, NA)
HORMONE THERAPY =
Only BREAST and PROSTATE cases may be coded as receiving
endocrine surgery or endocrine radiation
Dead
STATUS =
PLACE OF DEATH may not be blank
CAUSE OF DEATH and STATE DEATH CERT may not both be blank
White
RACE 1 =
RACE 2 =
RACE 3 =
RACE 4 =
RACE 5 =
For race combinations RACE 1 may not be 'White'
A specific race code may not occur more than once
ONC*2.11*15
Please install ONC*2.11*15 first. Installation Halted.
ONC*2.11*20
ONCO*2.11*20
Please install ONC*2.11*20 first. Installation Halted.
The Accession Year is not 2001.
GI stromal sarcomas (8936) are being collected via paper data form.
The Behavior Code is not 3 (Malignant).
Invalid Histology code.
Select section
2001 Patient Care Evaluation Study of Gastric Cancers
PATIENT INFORMATION
1400.6 1. CO-MORBID CONDITIONS (YES/NO).
1571 CO-MORBID CONDITION #1.......
1571.1 CO-MORBID CONDITION #2.......
1571.2 CO-MORBID CONDITION #3.......
1571.3 CO-MORBID CONDITION #4.......
1571.4 CO-MORBID CONDITION #5.......
1571.5 CO-MORBID CONDITION #6.......
1500 2. PRIOR EXPOSURE TO RADIATION...
1501 3. ALCOHOL CONSUMPTION...........
1572 4. DURATION OF TOBACCO USE.......
5. MENOPAUSAL STATUS AND HORMONE
REPLACEMENT THERAPY..........: NA, male patient
1502 5. MENOPAUSAL STATUS AND HORMONE REPLACEMENT THERAPY..........
1503 6. H2 BLOCKER/PROTON PUMP INHIBITOR USE................
1504 7. FAMILY HISTORY OF GASTRIC CANCER.......................
1573 8. PERSONAL HISTORY OF OTHER INVASIVE MALIGNANCIES PRIOR TO THIS CANCER DIAGNOSIS....//^S X=PHDEF
9. ASSOCIATED BENIGN CONDTIONS:
1505 H-PYLORI INFECTION...........
1506 DUODENAL ULCER...............
1507 GASTRIC ULCER................
1509 PERNICIOUS ANEMIA............
1510 POLYPS OF STOMACH............
1511 POLYPOSIS OF SMALL OR LARGE BOWEL.......................
1513 ATROPHIC GASTRITIS...........
1514 GASTRIC METAPLASIA...........
10. H-PYLORI DRUGS GIVEN:
1516 PROTON PUMP INHIBITORS.......
1518 BISMUTH COMPOUNDS............
1519 11. PRIOR INTRA-ABDOMINAL SURGERY.
1520 12. YEAR OF PRIOR GASTRIC RESECTION....................
CO-MORBID CONDITIONS (YES/NO) equals
CO-MORBID CONDITION #1 may not be blank
CO-MORBID CONDITION #1.......: 000.00 No co-morbidities
CO-MORBID CONDITION #2.......:
CO-MORBID CONDITION #3.......:
CO-MORBID CONDITION #4.......:
CO-MORBID CONDITION #5.......:
CO-MORBID CONDITION #6.......:
ANTIBIOTICS..................: H-pylori not present
PROTON PUMP INHIBITORS.......: H-pylori not present
H2 BLOCKERS..................: H-pylori not present
BISMUTH COMPOUNDS............: H-pylori not present
TUMOR INDENTIFICATION AND DIAGNOSIS
1521 13. PERFORMANCE STATUS AT INITIAL DIAGNOSIS....................
14. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
1523 FEVER/NIGHT SWEATS...........
1524 ACUTE HEMATEMESIS............
1525 TRANSFUSIONS FOR BLOOD LOSS..
1574 WEIGHT LOSS..................
1528 EARLY SATIETY................
15. INITIAL STAGING STUDIES:
1529 CT SCAN OF ABDOMEN...........
1530 CT SCAN OF CHEST.............
1531 CT PELVIS....................
1533 GALLIUM SCAN.................
1534 BIPEDAL LYMPHANGIOGRAM (LAG).
1536 PET SCAN.....................
1538 EUS (ENDOSCOPIC ULTRASOUND)..
1539 PERITONEAL LAVAGE............
16. LABORATORY STUDIES:
17. GASTROSCOPIC EXAMINATION RESULTS:
1545 CLINICAL/VISUAL EXAMINATION..
1546 18. GASTRO-ESOPHAGEAL JUNCTION (SIEWART TYPE II/III)........
19. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:
1547.3 LYMPH NODES..................
1548 20. DATE OF FIRST TISSUE DIAGNOSIS
23. MOLECULAR MARKERS:
1552 24. MITOTIC RATE..................
1553 25. TUMOR NECROSIS................
26. PHENOTYPE MODALITY USED:
1554 FLOW CYTOMETRY ON FRESH TISSUE......................
1554.1 IMMUNOHISTOCHEMISTRY ON FROZEN TISSUE......................
1554.2 IMMUNOHISTOCHEMISTRY ON PARAFIN EMBEDDED TISSUE.....
1554.3 MOLECULAR GENETICS...........
1554.4 POLYMERASE CHAIN REACTION TECHNIQUE..................
1554.5 SOUTHERN BLOT TECHNIQUE......
1555 27. ANN ARBOR STAGING.............
18. GASTRO-ESOPHAGEAL JUNCTION (SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)
21. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)
22. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)
24. MITOTIC RATE..................: NA (not leimyosarcoma)
25. TUMOR NECROSIS................: NA (not leimyosarcoma)
FLOW CYTOMETRY ON FRESH TISSUE......................: NA (not lymphoma)
IMMUNOCHEMISTRY ON FROZEN TISSUE......................: NA (not lymphoma)
IMMUNOHISTOCHEMISTRY ON PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)
MOLECULAR GENETICS...........: NA (not lymphoma)
POLYMERASE CHAIN REACTION TECHNIQUE...................: NA (not lymphoma)
SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)
27. ANN ARBOR STAGING.............: NA (not lymphoma)
FIRST COURSE OF TREATMENT - SURGERY
1556 28. ADHERENCE OF RESECTED PRIMARY SPECIMEN.....................
1557 29. MARGIN STATUS OF RESECTED PRIMARY SPECIMEN.............
30. EXTENT OF FREE MARGIN:
1558 PROXIMAL MARGIN..............
1558.1 DISTAL MARGIN................
31. RESECTION BEYOND STOMACH:
1559.1 TRANVERSE COLON..............
1559.5 ABDOMINAL WALL...............
1559.6 ADRENAL GLAND................
1559.8 SMALL INTESTINE..............
1560 PERIGASTRIC LYMPH NODES......
1560.1 COMMON HEPATIC LYMPH NODES...
1560.2 CELIAC LYMPH NODES...........
1560.3 SPLENIC LYMPH NODES..........
1560.4 OTHER INTRA-ABDOMINAL NODES..
1561 32. GROSSLY INVOLVED REGIONAL LYMPH NODES..................
1562 33. HCT (HEMATOCRIT) VALUES BEFORE TRANSFUSION..................
1563 34. TOTAL OPERATIVE BLOOD REPLACEMENT..................
1564 35. INTRA/PERI-OPERATIVE DEATH....
36. COMPLICATIONS REQUIRING RE-OPERATION:
1565 ANASTOMOTIC LEAK.............
1565.1 STUMP LEAK...................
1565.3 WOUND INFECTION..............
1565.6 DEAD BOWEL...................
1566 37. DATE OF SURGICAL DISCHARGE....
FIRST COURSE OF TREATMENT - RADIATION
442 38. REGIONAL DOSE (cGy)...........
1575 39. BOOST DOSE (cGy)..............
1567 40. INTRA-OPERATIVE RADIATION THERAPY, DOSE (cGy)..........
1568 41. CONCURRENT CHEMOTHERAPY.......
FIRST COURSE OF TREATMENT - CHEMOTHERAPY
42. TYPE OF CHEMOTHERAPEUTIC AGENTS ADMINISTERED:
1569 43. INTRAPERITONEAL CHEMOTHERAPY..
1577 44. CHEMOTHERAPEUTIC TOXICITY.....
1578 45. CHEMOTHERAPY/SURGERY SEQUENCE.
FIRST COURSE OF TREATMENT - IMMUNOTHERAPY
1570 46. ADMINSTRATION OF INTERFERON...
No surgery of the primary site was performed.
Proceed to data item 38.
No radiation therapy was administered.
Code data items 38-40 to 00000.
Do not answer data item 41, and proceed to data item 42.
38. REGIONAL DOSE (cGy)...........: 00000
39. BOOST DOSE (cGy)..............: Not administered
40. INTRA-OPERATIVE RADIATION
THERAPY, DOSE (cGy)..........: Not administered
41. CONCURRENT CHEMOTHERAPY.......:
No chemotherapy was administered.
Proceed to data item 46.
No immunotherapy administered.
Proceed to Treatment Complications.
TREATMENT COMPLICATIONS
COMPLICATION #1..............: 000.00 No complications
CASE REGISTRATION
81 48. INITIALS OF CASE ABSTRACTOR...
90 49. DATE CASE WAS ABSTRACTED......
PATIENT INFORMATION
1. CO-MORBID CONDITIONS:
CO-MORBID CONDITION #1.......: 000.00 No co-morbidities
CO-MORBID CONDITION #1.......:
CO-MORBID CONDITION #2.......:
CO-MORBID CONDITION #3.......:
CO-MORBID CONDITION #4.......:
CO-MORBID CONDITION #5.......:
CO-MORBID CONDITION #6.......:
2. PRIOR EXPOSURE TO RADIATION...:
3. ALCOHOL CONSUMPTION...........:
4. DURATION OF TOBACCO USE.......:
5. MENOPAUSAL STATUS AND HORMONE
REPLACEMENT THERAPY..........:
6. H2/BLOCKER PROTON PUMP
7. FAMILY HISTORY OF GASTRIC
8. PERSONAL HISTORY OF OTHER
INVASIVE MALIGNANCIES PRIOR
TO THIS CANCER DIAGNOSIS....:
9. ASSOCIATED BENIGN CONDITIONS:
H-PYLORI INECTION............:
DUODENAL ULCER...............:
GASTRIC ULCER................:
PERNICIOUS ANEMIA............:
POLYPS OF STOMACH............:
POLYPOSIS OF SMALL OR LARGE
ATROPHIC GASTRITIS...........:
GASTRIC METAPLASIA...........:
10. H-PYLORI DRUGS GIVEN:
PROTON PUMP INHIBITORS.......:
BISMUTH COMPOUNDS............:
11. PRIOR INTRA-ABDOMINAL SURGERY.:
12. YEAR OF PRIOR GASTRIC
Print Gastric Cancers PCE
TUMOR IDENTIFICATION AND DIAGNOSIS
13. PERFORMANCE STATUS AT INITIAL
14. SYMPTOMS PRESENT AT INITIAL DIAGNOSIS:
FEVER/NIGHT SWEATS...........:
ACUTE HEMATEMESIS............:
TRANSFUSIONS FOR BLOOD LOSS..:
WEIGHT LOSS..................:
EARLY SATIETY................:
15. INITIAL STAGING STUDIES:
CT SCAN OF ABDOMEN...........:
CT SCAN OF CHEST.............:
CT PELVIS....................:
GALLIUM SCAN.................:
BIPEDAL LYMPHANGIOGRAM (LAG).:
PET SCAN.....................:
EUS (ENDOSCOPIC ULTRASOUND)..:
PERITONEAL LAVAGE............:
16. LABORATORY STUDIES:
17. GASTROSCOPIC EXAMINATION RESULTS:
CLINICAL/VISUAL EXAMINATION..:
18. GASTRO-ESOPHAGEAL JUNCTION
(SIEWART TYPE II/III)........: NA (not C16.0 or C16.1)
(SIEWART TYPE II/III)........:
19. ANATOMIC SITE OF INITIAL HISTOLOGIC DIAGNOSIS:
LYMPH NODES..................:
20. DATE OF FIRST TISSUE DIAGNOSIS:
21. LAUREN'S CLASSIFICATION.......: NA (not adenocarcinoma)
22. GOSEKI'S CLASSIFICATION.......: NA (not adenocarcinoma)
23. MOLECULAR MARKERS:
24. MITOTIC RATE..................: NA (not leimyosarcoma)
25. TUMOR NECROSIS................: NA (not leimyosarcoma)
24. MITOTIC RATE..................:
25. TUMOR NECROSIS................:
26. PHENOTYPE MODALITY USED:
FLOW CYTOMETRY ON FRESH
TISSUE......................: NA (not lymphoma)
IMMUNOCHEMISTRY ON FROZEN
IMMUNOHISTOCHEMISTRY ON
PARAFIN EMBEDDED TISSUE.....: NA (not lymphoma)
MOLECULAR GENETICS...........: NA (not lymphoma)
POLYMERASE CHAIN REACTION
TECHNIQUE...................: NA (not lymphoma)
SOUTHERN BLOT TECHNIQUE......: NA (not lymphoma)
27. ANN ARBOR STAGING.............: NA (not lymphoma)
FLOW CYTOMETRY ON FRESH
IMMUNOCHEMISTRY ON FROZEN
IMMUNOHISTOCHEMISTRY ON
PARAFIN EMBEDDED TISSUE.....:
MOLECULAR GENETICS...........:
POLYMERASE CHAIN REACTION
SOUTHERN BLOT TECHNIQUE......:
27. ANN ARBOR STAGING..............:
FIRST COURSE OF TREATMENT - SURGERY
28. ADHERENCE OF RESECTED PRIMARY
29. MARGIN STATUS OF RESECTED
PRIMARY SPECIMAN.............:
30. EXTENT OF FREE MARGIN:
PROXIMAL MARGIN..............:
DISTAL MARGIN................:
31. RESECTION BEYOND STOMACH:
TRANVERSE COLON..............:
ABDOMINAL WALL...............:
ADRENAL GLAND................:
SMALL INTESTINE..............:
PERIGASTRIC LYMPH NODES......:
COMMON HEPATIC LYMPH NODES...:
CELIAC LYMPH NODES...........:
SPLENIC LYMPH NODES..........:
OTHER INTRA-ABDOMINAL NODES..:
32. GROSSLY INVOLVED REGIONAL
33. HCT (HEMATOCRIT) VALUES BEFORE
34. TOTAL OPERATIVE BLOOD
35. INTRA/PERI-OPERATIVE DEATH....:
36. COMPLICATIONS REQUIRING RE-OPERATION:
ANASTOMOTIC LEAK.............:
STUMP LEAK...................:
WOUND INFECTION..............:
DEAD BOWEL...................:
37. DATE OF SURGICAL DISCHARGE....:
#################### #################### ####################
#################### #################### ####################
#################### #################### ####################
#################### #################### ####################
#################### #################### ####################